{"id":"NCT00507416","sponsor":"Millennium Pharmaceuticals, Inc.","briefTitle":"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone","officialTitle":"Randomized Phase 3b Study of Three Treatment Regimens in Subjects With Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE, Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2007-07-26","resultsPosted":"2014-05-01","lastUpdate":"2014-05-01"},"enrollment":502,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Bortezomib","otherNames":["Velcade"]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]},{"type":"DRUG","name":"Melphalan","otherNames":[]},{"type":"DRUG","name":"Prednisone","otherNames":[]},{"type":"DRUG","name":"Thalidomide","otherNames":[]}],"arms":[{"label":"Bortezomib and Dexamethasone (VD)","type":"EXPERIMENTAL"},{"label":"Bortezomib, Thalidomide, and Dexamethasone (VTD)","type":"EXPERIMENTAL"},{"label":"Bortezomib, Melphalan and Prednisone (VMP)","type":"EXPERIMENTAL"}],"summary":"This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered candidates for high-dose chemotherapy and autologous stem cell transplantation.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"From randomization until disease progression. Median follow-up time was 43 months.","effectByArm":[{"arm":"Bortezomib and Dexamethasone","deltaMin":14.7,"sd":null},{"arm":"Bortezomib, Thalidomide, and Dexamethasone","deltaMin":15.4,"sd":null},{"arm":"Bortezomib, Melphalan and Prednisone","deltaMin":17.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":"0.458"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":235,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["26056177"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":88,"n":165},"commonTop":["Insomnia","Hyperuricaemia","Leukopenia","Weight decreased","Platelet count decreased"]}}